(Q57341699)

1

0 references

Michiko Matsuzaki-Kobayashi

2

0 references

Atsushi Takeda

3

0 references

Naoto Sugeno

4

0 references

Akio Kikuchi

5

0 references

Katsutoshi Furukawa

6

0 references

Mark A. Smith

8

0 references

Yasuto Itoyama

Molecular pathophysiology of Parkinson's disease

9

0 references

language of work or name

English

0 references

publication date

15 March 2006

0 references

published in

FEBS Letters

0 references

volume

580

0 references

issue

8

0 references

page(s)

2147-2152

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Alpha-synuclein in Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Cytotoxic and genotoxic potential of dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Could a loss of alpha-synuclein function put dopaminergic neurons at risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Increased dopamine and its metabolites in SH‐SY5Y neuroblastoma cells that express tyrosinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Accelerated alpha-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Histochemical features of stress-induced aggregates in alpha-synuclein overexpressing cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Fe(II)‐induced DNA damage in α‐synuclein‐transfected human dopaminergic BE(2)‐M17 neuroblastoma cells: detection by the Comet assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Dopamine covalently modifies and functionally inactivates parkin

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Iron in brain function and dysfunction with emphasis on Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Dopamine toxicity in neuroblastoma cells: role of glutathione depletion by L-BSO and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Wild-type but not Parkinson's disease-related ala-53 --> Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Neurodegenerative disease: amyloid pores from pathogenic mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018

alpha-Synuclein affects the MAPK pathway and accelerates cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.018